Pathologic response to preoperative therapy: Does it mean what we think it means?

Annals of Surgical Oncology

Volumn 16, Issue 6, 2009, Pages 1465-1479

  Mansour, John C ^a   Schwarz, Roderich E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; PACLITAXEL;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DISEASE MARKER; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; PANCREAS CANCER; PREOPERATIVE TREATMENT; PROGNOSIS; RECTUM CANCER; REVIEW; STOMACH CANCER; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS; NEOPLASTIC PROCESSES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 67349083499     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0374-z     Document Type: Review

References (121)

1. RP Abratt D Brune MA Dimopoulos J Kliment J Breza FP Selvaggi 2004 Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer Ann Oncol. 15 1613 1621 (Pubitemid 39562600)
2. J Blade A Lopez-Guillermo F Bosch F Cervantes JC Reverter E Montserrat 1994 Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients Br J Haematol 88 117 121 (Pubitemid 24293862)
3. SJ Horning 1993 Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol 20 75 88 (Pubitemid 23319044)
4. SK Apple F Suthar 2006 How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy? Breast 15 370 376 (Pubitemid 43840879)
5. K Kuroi M Toi H Tsuda M Kurosumi F Akiyama 2005 Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer Biomed Pharmacother 59 S387 S392 (Pubitemid 43303911)
6. K Kuroi M Toi H Tsuda M Kurosumi F Akiyama 2006 Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer Breast Cancer 13 38 48
7. M Kurosumi 2006 Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer Breast Cancer 13 254 259
8. JC Mansour L Tang M Shah D Bentrem DS Klimstra M Gonen 2007 Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 14 3412 3418 (Pubitemid 350160134)
9. B Brenner MA Shah MS Karpeh M Gonen MF Brennan DG Coit 2006 A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer Ann Oncol 17 1404 1411 (Pubitemid 44403435)
10. T Imamura H Iguchi T Manabe G Ohshio T Yoshimura ZH Wang 1995 Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis Pancreas 11 357 364
11. F Aktepe N Kapucuoglu I Pak 1996 The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer Histopathology 29 63 67 (Pubitemid 26232524)
12. AU Buzdar NK Ibrahim D Francis DJ Booser ES Thomas RL Theriault 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 (Pubitemid 46252462)
13. SD Heys AW Hutcheon TK Sarkar KN Ogston ID Miller S Payne 2002 Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial Clin Breast Cancer 3 S69 S74 (Pubitemid 35423140)
14. J Huober U Krainick-Strobel R Kurek D Wallwiener 2004 Neoadjuvant endocrine therapy in primary breast cancer Clin Breast Cancer 5 341 347 (Pubitemid 40109639)
15. DM Sataloff BA Mason AJ Prestipino UL Seinige CP Lieber Z Baloch 1995 Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J Am Coll Surg 180 297 306
16. BT Hennessy AM Gonzalez-Angulo GN Hortobagyi M Cristofanilli SW Kau K Broglio 2006 Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy Cancer 106 1000 1006 (Pubitemid 43297337)
17. B Fisher A Brown E Mamounas S Wieand A Robidoux RG Margolese 1997 Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483 2493 (Pubitemid 27289876)
18. BT Hennessy GN Hortobagyi R Rouzier H Kuerer N Sneige AU Buzdar 2005 Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy J Clin Oncol 23 9304 9311 (Pubitemid 46260188)
19. HM Kuerer LA Newman AU Buzdar KK Hunt K Dhingra TA Buchholz 1998 Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer Am J Surg 176 502 509 (Pubitemid 29056639)
20. HM Kuerer AA Sahin KK Hunt LA Newman TM Breslin FC Ames 1999 Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy Ann Surg 230 72 78 (Pubitemid 30190367)
21. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 (Pubitemid 28363030)
22. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 (Pubitemid 29075229)
23. P Bertheau F Lerebours N Mounier A de Roquancourt M Espié 2005 Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer Oncol Rep 14 513 520
24. EH Huang SL Tucker EA Strom MD [tmp] McNeese HM Kuerer GN Hortobagyi 2005 Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy Int J Radiat Oncol Biol Phys 62 351 357 (Pubitemid 40704449)
25. P Ellis I Smith S Ashley G Walsh S Ebbs M Baum 1998 Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer J Clin Oncol 16 107 114 (Pubitemid 28041586)
26. TA Buchholz SL Tucker L Masullo HM Kuerer J Erwin J Salas 2002 Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation J Clin Oncol 20 17 23 (Pubitemid 34032591)
27. JY Pierga E Mouret V Dieras V Laurence P Beuzeboc T Dorval 2000 Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer Br J Cancer 83 1480 1487
28. AM Neville R Bettelheim RD Gelber J Säve-Söderbergh BW Davis R Reed 1992 Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 696 705
29. M Castiglione-Gertsch C Johnsen A Goldhirsch RD Gelber CM Rudenstam J Collins 1994 The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up Ann Oncol 5 717 724 (Pubitemid 2151391)
30. I Barista E Baltali IH Güllü N Güler I Celik O Saraçbaşi 1996 Factors influencing the distribution of metastases and survival in metastatic breast carcinoma Am J Clin Oncol 19 569 573 (Pubitemid 26384704)
31. C Mazouni SW Kau D Frye F Andre HM Kuerer TA Buchholz 2007 Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers Ann Oncol 18 874 880 (Pubitemid 47054084)
32. ER Fisher J Wang J Bryant B Fisher E Mamounas N Wolmark 2002 Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 Cancer 95 681 695
33. VF Cocquyt PN Blondeel HT Depypere MM Praet VR Schelfhout OE Silva 2003 Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma Eur J Surg Oncol 29 361 367 (Pubitemid 36675693)
34. M Tubiana-Hulin D Stevens S Lasry JM Guinebretière L Bouita C Cohen-Solal 2006 Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution Ann Oncol 17 1228 1233 (Pubitemid 44288213)
35. K Akazawa Y Tamaki T Taguchi Y Tanji Y Miyoshi SJ Kim 2006 Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy Breast J 12 130 137
36. A Bottini A Berruti M Tampellini B Morrica A Brunelli E Gnocchi 1997 Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease Tumour Biol 18 301 310 (Pubitemid 27362333)
37. T Kanazawa S Akashi-Tanaka E Iwamoto M Takasugi T Shien T Kinoshita 2005 Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients Breast J 11 311 316 (Pubitemid 41726032)
38. MS Kwong GG Chung LJ Horvath BA Ward AD Hsu D Carter 2006 Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer Cancer J 12 212 221 (Pubitemid 43894338)
39. D Segara IE Krop JE Garber E Winer L Harris JR Bellon 2007 Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96 474 480 (Pubitemid 350044390)
40. M Tozaki S Uno T Kobayashi K Aiba K Yoshida H Takeyama 2004 Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI Radiat Med 22 246 253 (Pubitemid 39264801)
41. SJ Vinnicombe AD [tmp] MacVicar RL Guy JP Sloane TJ Powles G Knee 1996 Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation Radiology 198 333 340 (Pubitemid 26036832)
42. DC Abraham RC Jones SE Jones JH Cheek GN Peters SM Knox 1996 Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging Cancer 78 91 100 (Pubitemid 26189909)
43. C Rousseau A Devillers C Sagan L Ferrer B Bridji L Campion 2006 Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography J Clin Oncol 24 5366 5372 (Pubitemid 46623167)
44. JA Ajani R Komaki JB Putnam G Walsh J Nesbitt PW Pisters 2001 A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction Cancer 92 279 286 (Pubitemid 32664433)
45. JA Ajani G Walsh R Komaki J Morris SG Swisher JB Putnam Jr 2004 Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction Cancer 100 2347 2354 (Pubitemid 38657881)
46. E Ancona A Ruol S Santi S Merigliano VC Sileni H Koussis 2001 Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone Cancer 91 2165 2174 (Pubitemid 32476382)
47. LR Chirieac SG Swisher JA Ajani RR Komaki AM Correa JS Morris 2005 Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation Cancer 103 1347 1355 (Pubitemid 40410728)
48. JS Donington DL Miller MS Allen C Deschamps FC Nichols 3rd PC Pairolero 2003 Tumor response to induction chemoradiation: influence on survival after esophagectomy Eur J Cardiothorac Surg 24 631 636 discussion 636-7 (Pubitemid 37162533)
49. Y Gu SG Swisher JA Ajani AM Correa WL Hofstetter Z Liao 2006 The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation Cancer 106 1017 1025 (Pubitemid 43297339)
50. PR Rohatgi SG Swisher AM Correa TT Wu Z Liao R Komaki 2005 Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus Cancer 104 1349 1355 (Pubitemid 41356149)
51. KL Wang Q Yang KR Cleary SG Swisher AM Correa R Komaki 2006 The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation Cancer 107 1467 1474 (Pubitemid 44546905)
52. JI Geh SJ Bond SM Bentzen R Glynne-Jones 2006 Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response Radiother Oncol 78 236 244
53. AM Mandard F Dalibard JC Mandard J Marnay M Henry-Amar JF Petiot 1994 Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73 2680 2686 (Pubitemid 24166250)
54. MC Posner WE Gooding RJ Landreneau MM Rosenstein MR Clarke MS Peterson 1998 Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction Cancer J Sci Am 4 237 246 (Pubitemid 28354925)
55. PM Schneider SE Baldus R Metzger M Kocher R Bongartz E Bollschweiler 2005 Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg 242 684 692 (Pubitemid 41567124)
56. SG Swisher W Hofstetter TT Wu AM Correa JA Ajani RR Komaki 2005 Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT) Ann Surg 241 810 817 discussion 817-20 (Pubitemid 40604927)
57. AC Berger J Farma WJ Scott G Freedman L Weiner JD Cheng 2005 Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival J Clin Oncol 23 4330 4337 (Pubitemid 46207006)
58. RJ Korst AL Kansler JL Port PC Lee Y Kerem NK Altorki 2006 Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma Ann Thorac Surg 82 480 484 discussion 484-5 (Pubitemid 44080050)
59. NP Rizk E Venkatraman MS Bains B Park R Flores L Tang 2007 American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma J Clin Oncol 25 507 512 (Pubitemid 350002956)
60. C Duong DM Greenawalt A Kowalczyk ML Ciavarella G Raskutti WK Murray 2007 Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer Ann Surg Oncol 14 3602 3609 (Pubitemid 350160118)
61. H Kato M Fukuchi T Miyazaki M Nakajima N Tanaka T Inose 2007 Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography Anticancer Res 27 2627 2633 (Pubitemid 47227975)
62. Q Yang KR Cleary JC Yao SG Swisher JA Roth PM Lynch 2004 Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen Dis Esophagus 17 38 43 (Pubitemid 38807874)
63. SG Swisher J Erasmus M Maish AM Correa H Macapinlac JA Ajani 2004 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma Cancer 101 1776 1785 (Pubitemid 39314740)
64. K Ott WA Weber F Lordick K Becker R Busch K Herrmann 2006 Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction J Clin Oncol 24 4692 4698 (Pubitemid 46646244)
65. PT Lavin HW Bruckner SC Plaxe 1982 Studies in prognostic factors relating to chemotherapy for advanced gastric cancer Cancer 50 2016 2023 (Pubitemid 13203600)
66. AM Lowy PF Mansfield SD Leach R Pazdur P Dumas JA Ajani 1999 Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer Ann Surg 229 303 308 (Pubitemid 30191763)
67. JA Ajani PF Mansfield N Janjan J Morris PW Pisters PM Lynch 2004 Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma J Clin Oncol 22 2774 2780 (Pubitemid 41079894)
68. JA Ajani PF Mansfield CH Crane TT Wu S Lunagomez PM Lynch 2005 Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome J Clin Oncol 23 1237 1244 (Pubitemid 46202281)
69. JA Ajani K Winter GS Okawara JH Donohue PW Pisters CH Crane 2006 Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response J Clin Oncol 24 3953 3958 (Pubitemid 46630744)
70. F Dehdashti BA Siegel 2004 Neoplasms of the esophagus and stomach Semin Nucl Med 34 198 208 (Pubitemid 38887175)
71. K Herrmann K Ott AK Buck F Lordick D Wilhelm M Souvatzoglou 2007 Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: A comparative analysis J Nucl Med 48 1945 1950 (Pubitemid 350232302)
72. K Mukai Y Ishida K Okajima H Isozaki T Morimoto S Nishiyama 2006 Usefulness of preoperative FDG-PET for detection of gastric cancer Gastric Cancer 9 192 196 (Pubitemid 44426892)
73. K Ott U Fink K Becker A Stahl HJ Dittler R Busch 2003 Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial J Clin Oncol 21 4604 4610 (Pubitemid 46594034)
74. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 (Pubitemid 46148091)
75. L Rubbia-Brandt E Giostra C Brezault AD Roth A Andres V Audard 2007 Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann Oncol 18 299 304 (Pubitemid 46323097)
76. PJ Allen N Kemeny W Jarnagin R DeMatteo L Blumgart Y Fong 2003 Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases J Gastrointest Surg 7 109 115 discussion 116-7 (Pubitemid 36875808)
77. A Grothey EE Hedrick RD Mass S Sarkar S Suzuki RK Ramanathan 2008 Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107 J Clin Oncol 26 183 189
78. Engstrom PF. NCCN clinical practice guidelines in oncology-rectal cancer. NCCN clinical practice guidelines in oncology, National Comprehensive Cancer Network, 2007.
79. LJ Kuo MC Liu JJ Jian CF Horng TI Cheng CM Chen 2007 Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 14 2766 2772 (Pubitemid 47460637)
80. S Pucciarelli C Capirci U Emanuele P Toppan ML Friso GM Pennelli 2005 Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer Ann Surg Oncol 12 111 116 (Pubitemid 40486618)
81. TE Read MS [tmp] McNevin EK Gross HM Whiteford JL Lewis G Ratkin 2001 Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity Dis Colon Rectum 44 513 522 (Pubitemid 32336425)
82. TE Read JE Andujar PF Caushaj DR Johnston DW Dietz RJ Myerson 2004 Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status Dis Colon Rectum 47 825 831 (Pubitemid 38702600)
83. R Rengan PB Paty WD Wong JG Guillem M Weiser L Temple 2006 Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders Clin Colorectal Cancer 5 413 421
84. F Stipa DB Chessin J Shia PB Paty M Weiser LK Temple 2006 A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography Ann Surg Oncol 13 1047 1053 (Pubitemid 44337963)
85. C Berger A de Muret P Garaud S Chapet P Bourlier A Reynaud-Bougnoux 1997 Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications Int J Radiat Oncol Biol Phys 37 619 627 (Pubitemid 27175318)
86. P Das JM Skibber MA Rodriguez-Bigas BW Feig GJ Chang RA Wolff 2007 Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer Cancer 109 1750 1755 (Pubitemid 46668536)
87. YA Park SK Sohn J Seong SH Baik KY Lee NK Kim 2006 Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer J Surg Oncol 93 145 150 (Pubitemid 43235261)
88. F Bozzetti S Andreola D Baratti L Mariani SC Stani F Valvo 2002 Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response Ann Surg Oncol 9 444 449 (Pubitemid 34625803)
89. A Vanagunas DE Lin SJ Stryker 2004 Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy Am J Gastroenterol 99 109 112 (Pubitemid 38679111)
90. A Habr-Gama RO Perez W Nadalin SC Nahas U Ribeiro Jr Silva E Sousa AH Jr 2005 Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival J Gastrointest Surg 9 90 99 discussion 99-101 (Pubitemid 40037876)
91. SP Hiotis SM Weber AM Cohen BD Minsky PB Paty JG Guillem 2002 Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients J Am Coll Surg 194 131 135 discussion 135-6 (Pubitemid 34118868)
92. Moore HG, Gittleman AE, Minsky BD, Wong D, Paty PB, Weiser M, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47-86. (Pubitemid 38280578)
93. S Pucciarelli P Toppan ML Friso V Russo L Pasetto E Urso 2004 Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome Dis Colon Rectum 47 1798 1807 (Pubitemid 40064422)
94. CC Compton LP Fielding LJ Burgart B Conley HS Cooper SR Hamilton 2000 Prognostic factors in colorectal cancer College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 979 994 (Pubitemid 30602039)
95. MW Onaitis RB Noone R Fields H Hurwitz M Morse P Jowell 2001 Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival Ann Surg Oncol 8 801 806 (Pubitemid 34003329)
96. JN Wiig SG Larsen S Dueland KE Giercksky 2005 Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer J Surg Oncol 92 70 75 (Pubitemid 41416431)
97. C Rodel P Martus T Papadoupolos L Füzesi M Klimpfinger R Fietkau 2005 Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer J Clin Oncol 23 8688 8696 (Pubitemid 46211512)
98. TM Breslin KR Hess DB Harbison ME Jean KR Cleary AP Dackiew 2001 Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration Ann Surg Oncol 8 123 132 (Pubitemid 32199408)
99. RR White HB Xie MR Gottfried BG Czito HI Hurwitz MA Morse 2005 Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer Ann Surg Oncol 12 214 221 (Pubitemid 40568908)
100. CR Antonescu P Besmer T Guo K Arkun G Hom B Koryotowski 2005 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 4182 4190 (Pubitemid 40791584)
101. MV Blagosklonny 2005 Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance Cell Cycle 4 1693 1698 (Pubitemid 41827304)
102. MV Blagosklonny 2004 Antiangiogenic therapy and tumor progression Cancer Cell 5 13 17 (Pubitemid 38121592)
103. A Bedi BA Zehnbauer MI Collector JP Barber MS Zicha SJ Sharkis 1993 BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia Blood 81 2898 2902 (Pubitemid 23162107)
104. W Matsui CA Huff Q Wang MT Malehorn J Barber Y Tanhehco 2004 Characterization of clonogenic multiple myeloma cells Blood 103 2332 2336 (Pubitemid 38326254)
105. M Al-Hajj MS Wicha A Benito-Hernandez SJ Morrison MF Clarke 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 3983 3988 (Pubitemid 36418143)
106. HD Hemmati I Nakano JA Lazareff M Masterman-Smith DH Geschwind M Bronner-Fraser 2003 Cancerous stem cells can arise from pediatric brain tumors Proc Natl Acad Sci USA 100 15178 15183 (Pubitemid 37518036)
107. SK Singh ID Clarke M Terasaki VE Bonn C Hawkins J Squire 2003 Identification of a cancer stem cell in human brain tumors Cancer Res 63 5821 5828 (Pubitemid 37187480)
108. C Li DG Heidt P Dalerba CF Burant L Zhang V Adsay 2007 Identification of pancreatic cancer stem cells Cancer Res 67 1030 1037 (Pubitemid 46270758)
109. I Avital AL Moreira DS Klimstra M Leversha EB Papdopoulos M Brennan 2007 Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation Stem Cells 25 2903 2909 (Pubitemid 350127875)
110. JJ Erasmus RF Munden MT Truong JJ Ho WL Hofstetter HA Macapinlac 2006 Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging J Thorac Oncol 1 478 486 (Pubitemid 47181426)
111. MC Tan DC Linehan WG Hawkins BA Siegel SM Strasberg 2007 Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response J Gastrointest Surg 11 1112 1119
112. CM Kang JY Kim GH Choi KS Kim JS Choi WJ Lee 2007 The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer J Surg Res 140 31 35 (Pubitemid 46669540)
113. Borowitz M, Westra W, Cooley LD, et al. Pathology and laboratory medicine. In: Abeloff MD, editor. Clinical oncology. Philadelphia: Elsevier; 2004.
114. TJ Polascik JE Oesterling AW Partin 1999 Prostate specific antigen: a decade of discovery-what we have learned and where we are going J Urol 162 293 306 (Pubitemid 29434327)
115. V Goral H Yesilbagdan A Kaplan D Sit 2007 Evaluation of CA 72-4 as a new tumor marker in patients with gastric cancer Hepatogastroenterology 54 1272 1275 (Pubitemid 47013952)
116. N Li J Zhang Y Liang J Shao F Peng M Sun 2007 A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells? J Proteome Res 6 3304 3312 (Pubitemid 47310214)
117. GY Locker S Hamilton J Harris JM Jessup N Kemeny JS Macdonald 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 5313 5327 (Pubitemid 46631379)
118. AH Ko J Hwang AP Venook JL Abbruzzese EK Bergsland MA Tempero 2005 Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer Br J Cancer 93 195 199 (Pubitemid 41133205)
119. O Micke F Bruns R Kurowski E Horst AF de Vries JW Hausler 2003 Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy Int J Radiat Oncol Biol Phys 57 90 97 (Pubitemid 36959743)
120. Y Fong J Fortner RL Sun MF Brennan LH Blumgart 1999 Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 309 318 discussion 318-21 (Pubitemid 30191861)
121. AM Lowy BW Feig N Janjan TA Rich PW Pisters JA Ajani 2001 A pilot study